NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding EXACT Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $89.40 -0.38 (-0.42 %) (As of 01/17/2020 01:36 PM ET) Add Compare Today's Range$88.81Now: $89.40▼$90.3650-Day Range$80.77MA: $91.69▼$104.4452-Week Range$73.63Now: $89.40▼$123.99Volume64,072 shsAverage Volume2.78 million shsMarket Capitalization$11.61 billionP/E RatioN/ADividend YieldN/ABeta1.35 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS Previous Symbol CUSIP30063P10 CIK1124140 Webhttp://www.exactsciences.com/ Phone608-535-8815Debt Debt-to-Equity Ratio0.67 Current Ratio2.75 Quick Ratio2.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$454.46 million Price / Sales25.54 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book16.14Profitability EPS (Most Recent Fiscal Year)($1.36) Net Income$-175,150,000.00 Net Margins-29.83% Return on Equity-29.06% Return on Assets-12.63%Miscellaneous Employees1,977 Outstanding Shares129,832,000Market Cap$11.61 billion Next Earnings Date2/20/2020 (Estimated) OptionableOptionable Receive EXAS News and Ratings via Email Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EXAS Rates by TradingView EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions What is EXACT Sciences' stock symbol? EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS." How were EXACT Sciences' earnings last quarter? EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Tuesday, October, 29th. The medical research company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.10. The medical research company earned $218.81 million during the quarter, compared to the consensus estimate of $216.14 million. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. The company's revenue for the quarter was up 85.0% on a year-over-year basis. During the same period last year, the company earned ($0.37) earnings per share. View EXACT Sciences' Earnings History. When is EXACT Sciences' next earnings date? EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for EXACT Sciences. What guidance has EXACT Sciences issued on next quarter's earnings? EXACT Sciences updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $294-296 million, compared to the consensus revenue estimate of $265.89 million. What price target have analysts set for EXAS? 16 brokers have issued 12-month price objectives for EXACT Sciences' stock. Their forecasts range from $102.00 to $143.00. On average, they anticipate EXACT Sciences' share price to reach $122.93 in the next year. This suggests a possible upside of 37.6% from the stock's current price. View Analyst Price Targets for EXACT Sciences. What is the consensus analysts' recommendation for EXACT Sciences? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences. What are Wall Street analysts saying about EXACT Sciences stock? Here are some recent quotes from research analysts about EXACT Sciences stock: 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (10/17/2019) 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019) Has EXACT Sciences been receiving favorable news coverage? Press coverage about EXAS stock has trended very negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. EXACT Sciences earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for EXACT Sciences. Are investors shorting EXACT Sciences? EXACT Sciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,380,000 shares, an increase of 11.5% from the December 15th total of 12,900,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is currently 6.9 days. Currently, 11.2% of the company's shares are sold short. View EXACT Sciences' Current Options Chain. Who are some of EXACT Sciences' key competitors? Some companies that are related to EXACT Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of EXACT Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), Advanced Micro Devices (AMD), Square (SQ) and Netflix (NFLX). Who are EXACT Sciences' key executives? EXACT Sciences' management team includes the folowing people: Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)Mr. Graham P. Lidgard, Chief Science Officer (Age 70)Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Mark Stenhouse, Pres of Cologuard (Age 52) Who are EXACT Sciences' major shareholders? EXACT Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (0.11%), United Services Automobile Association (0.03%), Curbstone Financial Management Corp (0.02%), Grassi Investment Management (0.01%), Patten & Patten Inc. TN (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences. Which institutional investors are selling EXACT Sciences stock? EXAS stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Gateway Investment Advisers LLC, IFP Advisors Inc, Meridian Wealth Management LLC, Artemis Investment Management LLP and AE Wealth Management LLC. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences. Which institutional investors are buying EXACT Sciences stock? EXAS stock was acquired by a variety of institutional investors in the last quarter, including United Services Automobile Association, Curbstone Financial Management Corp, American National Bank, Polianta Ltd, Grassi Investment Management, Perkins Coie Trust Co, Patten & Patten Inc. TN and DNB Asset Management AS. View Insider Buying and Selling for EXACT Sciences. How do I buy shares of EXACT Sciences? Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is EXACT Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $89.35. How big of a company is EXACT Sciences? EXACT Sciences has a market capitalization of $11.60 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences. What is EXACT Sciences' official website? The official website for EXACT Sciences is http://www.exactsciences.com/. How can I contact EXACT Sciences? EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815. MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 824 (Vote Outperform)Underperform Votes: 507 (Vote Underperform)Total Votes: 1,331MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: How to build a Fibonacci channel
